Compare Bristol-Myers Squibb Co (BMY) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs DexCom, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while DexCom, Inc. trades at $90.65 (market cap $33.79B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.8× DexCom, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| BMY | DXCM | |
|---|---|---|
Market Cap | $129.94B | $33.79B |
Sector | Health | Health |
52-Week High | $65.89 | $89.53 |
52-Week Low | $42.60 | $54.84 |
Enterprise Value | $163.92B | $33.24B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
